Deep learning assisted analysis of biomarker changes in refractory neovascular AMD after switch to faricimab

Table 2 Changes in visual acuity, biomarker levels, and treatment intervals over the study period

	BCVA (logMAR)	CRT (µm)	SRF (voxel)	IRF (voxel)	SHRM (voxel)	fvPED (voxel)	Choroid (voxel)	Injection interval (days)
mo0	0.30	342.7	958	22	41	10,320	224,499	35
mo3	0.20	296.6	2	5	1	7543	209,143
mo9	0.20	310.2	7	11	9	8486	216,446	56
iqr (mo0)	0.40	117.1	4600	400	219	17,376	125,858	15
iqr (mo3)	0.20	84.3	32	32	80	15,239	107,341
iqr (mo9)	0.30	93.6	220	154	181	14,615	127,956	20
p-value (mo0-mo3)	> 0.9999	< 0.0001	< 0.0001	0.0399	0.0044	< 0.0001	0.0011
p-value (mo0-mo9)	0.7067	< 0.0001	< 0.0001	0.6475	0.1906	0.0004	0.0256	< 0.0001
p-value (mo3-mo9)	0.9815	0.0698	> 0.9999	0.6475	0.3153	0.5399	> 0.9999

This table presents the median values (with interquartile ranges) of best-corrected visual acuity (BCVA, logMAR), central retinal thickness (CRT, µm), and key OCT biomarkers (SRF: subretinal fluid; IRF: intraretinal fluid; SHRM: subretinal hyperreflective material; fvPED: fibrovascular pigment epithelium detachment; choroidal volume) at baseline (mo0, day of switch), after three months (mo3, day of fourth Faricimab injection), and at nine months (mo9). The injection interval (days) before and after switching to Faricimab is also reported. Pairwise comparisons were conducted using the Friedman ANOVA test, with significant p-values (p < 0.05) highlighted in bold

ISSN: 2056-9920